Introduction
Traumatic brain injury (TBI) is a major cause of death and disability worldwide, leading to immense personal suffering to victims and relatives, and high costs to society. Injuries are the leading cause of death between the ages of 15 and 44, and head trauma accounts for the majority of all trauma deaths. Today, at least 11.5 million people live with TBI-related disability, impairment, complaint or handicap in Europe (6.2 million) and the USA (5.3 million) alone [1 ,2] .
Depending on the severity of injury, the medical management of brain-injured patients currently includes specialized prehospital care, clinical (intensive) care, and, for some, long-term rehabilitation, but lacks clinically proven effective management with neuroprotective agents to limit pathophysiologic cascades or enhance repair. The enormous burden of TBI, however, clearly supports the need for such neuroprotective agents. Translating promising experimental results into clinical benefit has proven an extremely complex issue. First, although many pathophysiologic cascades inducing secondary damage have been identified, it remains uncertain which of these are active in individual patients and at what time after injury. Moreover, many pathways may initially have detrimental effects, but at later stages can be protective. Second, clinical trials have suffered from inadequacy in their design and analysis, not in the least part due to heterogeneity of the population and variability in treatment approaches [3] .
Rationale for treatment: primary and secondary injury
Brain trauma results in brain damage and dysfunction from both primary injury (due to biomechanical effects) and subsequent secondary damage due to activation of pathophysiologic cascades. These are further aggravated by secondary insults. Early detection of such secondary insults, including intracranial insults (e.g. mass lesions, increased intracranial pressure) and systemic insults (e.g. hypoxia, hypotension), followed by appropriate intervention currently forms the basis of clinical management [4] .
Secondary damage consists of seemingly innumerable complex biochemical and cellular pathways that influence progression of the primary injury. The primary goal of neuroprotection is to prevent and/or reduce secondary damage and to enhance repair [5] . Over the past decades our understanding of the pathophysiology of TBI has greatly increased and based on this understanding numerous pharmacological therapies have been developed, tested and proven effective in the treatment of experimental TBI. To date, however, promising experimental results have not been translated into successful clinical trials, and hence the cornerstone of management of TBI patients remains the prevention of initial injury and the minimization or reversal of secondary insults. The excitement about the new knowledge of the neurobiology and neuropharmacology of TBI should not detract from the absolute importance of correcting hypoxia, hypotension, raised intracranial pressure and other causes of secondary ischemic insult [6, 7] . On the other hand, we should not be discouraged by negative results and difficulties in previous clinical trials, but continue our search for effective neuroprotective drugs for TBI patients in order to further improve outcome of this devastating disease.
Neuroprotective strategies
The complex pathobiology of TBI offers numerous targets for potential neuroprotective agents. Many of these have been or will be investigated in experimental models of TBI (Table 1 [ 8 ,9-13] ). The few that made it into clinical trials join a growing list of neuroprotective agents without proven clinical benefit (Table 2 [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] ). The focus of this review is on neuroprotective agents that have recently been evaluated in clinical trials and are currently under clinical evaluation, as well as on those that appear promising and are likely to undergo clinical evaluation in the near future.
Excitatory neurotransmitter antagonism
Disturbances in neurotransmitter concentration occur frequently following TBI. Excitotoxicity refers to an excessive release of excitatory neurotransmitters (primarily glutamate) initiating various pathophysiologic processes including excessive calcium influx in neurons, resulting in neuronal cell death [10] . High concentrations of extracellular glutamate have been demonstrated in both experimental models and clinical patients with TBI. Experimental research has elucidated many aspects of excitotoxicity and identified a number of glutamate antagonists acting either pre-or postsynaptically on N-methyl-D-aspartic acid (NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazolyl-propionic acid (AMPA)/kainate or metabotropic receptors, in a competitive, noncompetitive or modulating way. However, glutamate receptors are of utmost importance to normal functioning, so antagonism of excessive excitotoxic activity must be achieved Neuroprotection in traumatic brain injury Schouten 135 Table 1 Neuroprotective strategies evaluated in experimental traumatic brain injury
Pharmacological target Remarks
Excitatory amino acids Numerous compounds have been evaluated and reviewed elsewhere [8 ,10] . New compounds with different pharmacological profiles (e.g. memantine) require further experimental evaluation.
Calcium channels
Extensively studied, also in clinical TBI (Nimodipine and SNX-111); the short time frame following injury seems to limit further clinical use. Scavenging oxygen radicals Tirilazad Mesylate, PEG-SOD and Lubeluzole have been clinically evaluated; many new compounds are at least promising in experimental TBI. Inflammation A double-edged sword in TBI, both detrimental and beneficial. The massive inflammatory response is a high potential target for neuroprotection, with special attention for NO inhibitors, nitrones and nitroxides.
Caspases
Caspases are important enzymes in apoptotic cell death known to occur following TBI. It is however still a matter of debate whether apoptosis is a good or bad thing compared to necrosis following TBI.
Calpains
Calcium-dependent proteases involved in cytoskeletal remodeling. Calpain inhibitors in experimental TBI reduce damage to fiber tracts, and therefore are of major interest in axonal injury.
Hormonal treatment
Progesterone is currently being evaluated in a clinical trial. Steroids have been extensively studied in the past. Experimental compounds attracting a lot of attention are dehydroepiandrosterone, thyrotropin-releasing hormone and their analogs. Neurotransmission
Widespread changes in neurotransmitters occur following TBI. All compounds interfering in cathecholamine, serotonin, histamine, g-aminobutyric acid (GABA) and acetylcholine metabolism are therefore of potential interest following TBI. Cognitive problems and depression frequently present following TBI, which might benefit from this approach, although a rationale for more acute administration exists.
Neurotrophic factors
These growth/survival factors effectively reduce apoptosis and improve functional outcome in experimental TBI. Many questions about dosage, time-window and route of administration remain to be answered. Coagulation
Recombinant human factor VII has been evaluated in a clinical trial. Coagulation disorders are common following TBI, relate to outcome, and will be a hot topic for future research. Controversies regarding treatment of microvascular thrombosis and progressive hemorrhagic contusions require attention [11] . Anticonvulsants
Seizures occur frequently following TBI, and anticonvulsants may reduce early seizures. In addition, acute administration can be neuroprotective [12, 13] .
Immunophilin ligands
Cyclosporin A is currently being evaluated in a clinical trial, other compounds are under experimental investigation.
Minocycline
Minocycline is a broad-spectrum antibiotic, shown to be neuroprotective in experimental studies.
Others
In experimental research additional hot topics far from translation into clinical trials are neurogenesis, improvement of axonal outgrowth and stem-cell transplantation, although for the latter a small clinical trial in pediatric TBI has been initiated.
TBI, traumatic brain injury. Neuroprotective strategies are discussed more extensively in [8 ,9] . without interference in normal function [25] . Some highly neuroprotective NMDA antagonists have not been evaluated in clinical trials because of concerns of psychotropic side effects whereas for other compounds trials were terminated prematurely due to excess mortality in concomitant stroke trials. Recently, Traxoprodil, a second-generation NMDA antagonist that selectively targets NMDA receptors containing the NR2B subunit, has been evaluated in a clinical trial. Traxoprodil treatment was well tolerated and, although not statistically significant, resulted in increased favorable outcome and reduced mortality, which was more pronounced in the more severe subset of patients [26] . Dexanabinol is a synthetic cannabinoid devoid of psychotropic activity, but with strong neuroprotective potential due to antioxidant, anti-inflammatory and antiexcitotoxic properties. This compound was recently evaluated in a phase III trial and found safe, but not efficacious in the treatment of TBI [27 ] . Efficacy of blocking excitotoxic responses following TBI as well as other insults to the central nervous system, to date, remains unproven [28, 29] . Termination of trials before definitive evidence could be obtained, incomplete publication of data and underpowered studies limit definitive conclusions for this group of neuroprotective drugs. New drugs with different pharmacological profiles are currently under investigation in experimental TBI and show promising results. Translation into clinical trials should only occur in well designed trials based on what we have learned from previous trials.
Magnesium
Magnesium plays an important role in normal cellular functioning, and has demonstrated neuroprotective properties in experimental studies in models of cerebral ischemia as well as TBI. Magnesium treatment results in reduction of cerebral edema and neuronal cell death, and attenuated motor impairment and cognitive dysfunction following experimental TBI [30, 31] . One of the seemingly great advantages of magnesium, besides being inexpensive and widely available, is its multidirectional effect. Where other neuroprotective compounds usually interfere with just one pathophysiological mechanism, magnesium exerts its neuroprotective effects among others by noncompetitive NMDA receptor blockade, inhibition of presynaptic excitatory neurotransmitter release, suppression of cortical spreading depression, and blockade of voltage-gated calcium channels. Despite the solid amount of experimental evidence concerning the neuroprotective effects of magnesium, a recently completed randomized double-blind trial evaluating the efficacy of a 5-day continuous magnesium administration in 499 patients with moderate or severe TBI was unable to show neuroprotective effects and even indicated a possibility of harm [32 ] . The absence of efficacy is consistent with a recently reported stroke trial [33] . Possible statistical and methodological causes (e.g. lack of power to detect differences) of these negative results have not been identified. Even though magnesium administration (dose, start time, duration, concentration) in these studies was based on positive preclinical data, and targeted serum levels of magnesium were achieved, availability of magnesium in cerebrospinal fluid (CSF) or cerebral extracellular fluid might be a concern [34] [35] [36] . Further studies to elucidate the relationships between total and ionized concentrations of magnesium in serum and CSF at different times following clinical TBI may hopefully provide an explanation for the negative results of recent clinical trials.
Mitochondrial dysfunction
Mitochondria, as the centers of aerobic metabolism, show marked dysfunction following experimental and clinical TBI, contributing to cell death through several mechanisms. Increased mitochondrial calcium results in decreased ATP production and generation of reactive oxygen species as well as increased permeability of the inner mitochondrial membrane. The opening of the mitochondrial permeability transition pore is responsible for mitochondrial swelling and membrane rupture, resulting in cell death. Mitochondrial dysfunction can be attenuated by inhibitors of mitochondrial permeability transition such as cyclosporin A and its derivatives [37] . Based on preclinical data cyclosporin A has been evaluated in two phase II clinical trials, and was found to improve cerebral perfusion pressure and cerebral metabolism, as evaluated with microdialysis. Cyclosporin A is considered safe in TBI patients, and its CSF pharmacokinetics in the injured central nervous system have been elucidated, supporting the initiative for a phase III clinical trial, which is currently being designed [38 ,39,40] .
In experimental research, blockage of N-type voltagegated calcium channels by ziconotide (SNX-111) has been shown to induce partial restoration of mitochondrial function, but a clinical trial was terminated prematurely because of increased mortality in the treatment group. Newly developed, more selective N-type voltage-gated calcium-channel blockers like SNX-185 have better bioavailability, and appear neuroprotective in experimental models, but will need additional preclinical evaluation [41] .
Erythropoietin
Erythropoietin is a kidney-derived cytokine regulating hematopoiesis, and has recently been recognized as being neuroprotective. Abundant expression of erythropoietin and its receptor in most of the cell types in the central nervous system exists, and in response to hypoxia or excitotoxicity this expression is increased, suggesting a central role in endogenous protection from deleterious stimuli [42] . Erythropoietin has been shown to be neuroprotective in experimental models of stroke, and following experimental TBI treatment with erythropoietin leads to decreased lesion volume and improved functional outcome, possibly by limiting the inflammatory reaction [43] . Based on these experimental data clinical trials were initiated and the safety of erythropoietin administration in stroke patients was confirmed. A doubleblind proof-of-concept trial showed no adverse events, and suggested improved functional outcome in erythropoietin-treated patients [44] . These results prompted further clinical research, which is currently being conducted as a multicenter phase II/III trial in stroke patients, as well as an additional pharmacokinetic study evaluating CSF erythropoietin following systemic administration [45] . In TBI, a randomized phase II clinical trial is currently ongoing in Wisconsin, USA. This trial focuses primarily on moderate TBI patients, and instead of using the Glasgow Outcome Score evaluates neuronal cell-death markers as a primary outcome measure.
Hormones
There has been considerable debate about sex differences in outcome following TBI, but a large meta-analysis suggests that no differences in outcome between men and women exist in outcome following TBI [46] . This debate, however, together with gender difference in treatment response and outcome in experimental TBI, stimulated research directed at the role of sex steroids following TBI. Both progesterone and estrogen may exert neuroprotective effects [47] . Based on experimental research, progesterone is thought to exert its neuroprotective effects through a variety of mechanisms including a decrease of edema formation due to changes in the blood-brain barrier and modulation of g-aminobutyric acid (GABA)-ergic neurotransmission resulting in decreased excitotoxicity. In addition progesterone inhibits apoptosis and reduces gliosis and the posttraumatic inflammatory response [48, 49] . Allopregnanolone, a metabolite of progesterone, has also been shown to be neuroprotective, and might even be more effective than progesterone [50] . Both progesterone and allopregnanolone improve neuronal survival and functional recovery following experimental TBI [51] .
In experimental TBI estrogen has shown to possess antioxidant and antiapoptotic properties, and improves cerebral blood flow. However, estrogen supplementation in females increased mortality following experimental brain injury [47] , and most studies evaluating estrogen used pretreatment paradigms, raising questions about the value of estrogen in clinical TBI.
The wealth of experimental data on neuroprotective effects of progesterone together with adequate pharmacokinetic studies [52] resulted in a phase II clinical trial which concluded that no serious adverse events occurred due to progesterone administration in TBI patients. Even more interesting was the observation that, in moderate TBI survivors treated with progesterone, the outcome was better than in those treated with placebo [53] . A large multicenter study to prove what this study suggests has been initiated by the authors.
Bradykinin antagonists
Increased production of kinins has been reported following brain trauma, and their interaction with the constitutive B2-bradykinin receptor has been shown to be important in the development of postinjury inflammation-induced secondary damage. Specific inhibition of the B2-bradykinin receptor is considered a promising strategy for neurorotection. Experimental data support this strategy, and recently a phase I clinical trial to investigate the pharmacokinetics of Anatibant, a selective potent bradykinin receptor antagonist, was conducted and published [54] . Currently a phase II safety study is being conducted on 500 patients with TBI.
Nitric oxide and inhibitors of nitric oxide synthases
Nitric oxide is a key factor in the development of secondary injury, regulating the dilation of blood vessels and acting as chemotoxin during inflammatory processes. Nitric oxide is synthesized from L-arginine by the enzyme nitric oxide synthase (NOS), of which four isoforms have been identified. Three of these are constitutive and one inducible [55] . The three constitutive isoforms are neuronal NOS, endothelial NOS and mitochondrial NOS. The fourth isoform is the inducible NOS (iNOS), which is induced under pathological conditions [55] [56] [57] .
In excess, nitric oxide is potentially neurotoxic because it contributes to excitotoxic neuronal death, generates cytotoxic peroxynitrites, damages DNA directly, inhibits DNA synthesis, inhibits mitochondrial respiration, and has been associated with apoptotic cell death [58] . In addition to producing nitric oxide, NOSs are also known to produce considerable amounts of the free radicals superoxide and hydrogen peroxide. This occurs particularly when substrate levels fall below those required to saturate the enzyme. This mechanism is called uncoupling of NOS [59, 60] . Following TBI, nitric oxide synthesis is also activated by inflammation, which is initiated by both primary and secondary injuries. Proinflammatory cytokines can induce iNOS, thereby promoting persistent iNOS over-activation for several days after injury [61] . iNOS is mainly expressed in macrophages, microglia and infiltrating neutrophils recruited from the blood and thus has a substantially greater capacity to synthesize nitric oxide than endothelial NOS [58, 61] . During the course of the pathophysiological process triggered by TBI, nitric oxide accumulates in the brain immediately after injury, as well as several hours or days later.
Various studies have shown that nitric oxide and the NOS pathways are involved, both positively and negatively, in the secondary injury cascade following injury. These pathways, and the recognition of the importance of nitric oxide in modulating regional cerebral blood flow, indicate a promising treatment target. Overall, experimental studies with inhibitors of NOS have shown beneficial effects, in particular with inhibitors of neuronal NOS and iNOS [8 ] .
Other studies, however, failed to show benefit and a few even show deleterious effects (see [8 ] for references). These differences may reflect differential effects of agents investigated on the different isoforms of NOS as well as time-dependent influences. A new drug currently under investigation is the compound VAS203, a structural analog of 5678-tetrahydro-l-biopterin (BH4), the endogenous cofactor of NOS, and one of the most potent inhibitors of NOSs discovered so far. This compound competitively displaces BH4 from NOS and thus inhibits the formation of nitric oxide, but does not interact with the binding site of the substrate (L-arginine) [62] . Further, VAS203 is capable of reducing uncoupling of NOS, with an additional effect, the inhibition of increased superoxide production.
Translational neuroprotection: neuroprotection from bench to bedside
The neuroprotective agents that fail in clinical trials have all been proven effective in experimental models. One could question whether the current models of TBI adequately mimic human TBI. Many aspects of human TBI, either focal or diffuse, are reflected by the different experimental models, but experimental models cannot reproduce the entire heterogeneous spectrum of clinical TBI [63] . Additional concerns exist about the severity of experimental injuries as well as ultra-early or even pretreatment paradigms in experimental TBI. Extrapolation of results obtained in animals to clinical setting will remain problematic.
In 'early' TBI trials patient inclusion was primarily based on Glasgow Coma Score on admission ( Table 2 ). The actual presence of the pathophysiological mechanism that was targeted with the neuroprotective compound that was studied, however, has hardly or never been confirmed. The presence of certain pathophysiological mechanisms in patients should be the basis of inclusion in a clinical trial evaluating the compound that interferes with this mechanism in a hopefully beneficial manner. In other words: diffuse axonal injury patients and subdural hematoma patients should not be included in the same trial even though their Glasgow Coma Scores on admission are identical. We should select and include patients in trials that are likely to benefit from the evaluated treatment [64] .
Similarly, mild and moderate TBI may be considered completely different diseases than severe TBI. Unsuccessful clinical trials in which the subpopulation of moderately injured patients responded to therapy (e.g. [53] ) raise the question of whether trials should not focus more on moderate or even mild TBI patients whose brains actually are 'salvageable'. This population remains poorly represented in clinical trials, but constitutes the majority of all TBI worldwide.
To date, both clinical trials and experimental research have focused on the evaluation of a single potential neuroprotective compound at a time when it is considered unlikely that one 'magic bullet' will improve outcome in all subtypes of TBI. Serious consideration should be given to the possibility of combination therapies in which multiple compounds are administered sequentially, each in their own appropriate therapeutic time window.
Another major concern in clinical trials is the uncertainty about pharmacokinetics in the TBI patient, which are considerably different from the normal physiological situation. In recent phase III trials drug administration was based on specifically designed phase II trials [32 ,40] . More detailed pharmacokinetic studies are advocated by some, in which, in addition to the target, serum concentrations in CSF or cerebral extracellular fluid should be monitored [34, 57] . In this development, cerebral microdialysis is likely to become an increasingly important monitoring tool for diagnosis (presence of a pathophysiological mechanism in a patient), drug monitoring (measurement of drug concentration in the target organ) and outcome (surrogate outcome markers) in clinical TBI [65] .
Outcome
Pharmaceutical clinical trials in TBI, to date, have been largely unsuccessful [66 ] . To improve the quality of future clinical trials it is imperative that all data, including negative data, are published. Unfortunately, studies with negative results have not always been pulished (Table 2 ). In addition, trials have been prematurely terminated by sponsors because of interim analysis or (primarily psychomimetic) adverse effects in concurrent stroke trials. The question remains whether adverse effects leading to termination of clinical trials in stroke should have the same consequence in TBI trials because the average TBI patient, in contrast to the average stroke patient, is younger and -more importantly -comatose and fully sedated at the time of drug administration.
The primary end point in most TBI trials to date has been the dichotomized Glasgow Outcome Score (favorable/ unfavorable). The use of this scale, together with the hypothesis of most trials that a 10% increase in favorable outcome is considered a positive result, has led to negative trial results. Although reported as negative, many trials showed some improvement in outcome, but this was not statistically significant, indicating that neither efficacy nor inefficacy of the tested compound was proven.
In the recently published Dexanabinol trial, a new statistical method to reduce the effect of differences in initial prognostic risk factors on outcome analysis has been introduced. This so-called sliding dichotomy reduces the effect of differences in initial prognostic risk on outcome analysis, and thereby improves statistical power [27 ,67] . Somewhat similar, an improved outcome measure was introduced in the recently published magnesium trial. A composite outcome measure consisting of mortality, seizures, functional measures and neuropsychological tests was used as a primary outcome in this study, and is suggested to be more sensitive for the detection of a treatment effect [32 ] . The value of such composite outcomes, however, remains to be further evaluated in additional clinical trials.
In addition to clinical outcome markers there is an argument that surrogate outcome markers, like intracranial pressure, improved lactate/pyruvate ratio, or other biochemical markers, can be used to reflect therapeutic efficacy. Such surrogate outcome markers, however, would have to correlate with outcome, and this has not been proven to date, even for the most studied surrogate outcome marker, intracranial pressure.
A further complicating factor in clinical trials to date has been the limited standardization of treatment. Analysis of multicenter trials has shown heterogeneities in the patient population and treatment approaches, which have not been corrected for by covariate adjustment [68, 69] . In contrast, generalization of results from single-center trials is not necessarily valid, as a result of differences in treatment. Adherence to treatment protocols using evidence-based guidelines is likely to reduce heterogeneity in multicenter clinical trials [4] .
Conclusion
TBI is a major central-nervous-system disorder, with enormous burden to individual patients and society. Although extensive preclinical research has identified numerous effective neuroprotective agents, none of these agents has been proven to be effective in clinical trials. Before translation into clinical trial, experimental evidence should be strong, based on multiple experiments, preferably in multiple models, and include pharmacokinetic analysis. Successful translation of compounds into clinical trials will probably require a more mechanistic approach, in which only patients with the proven presence of a certain pathophysiological mechanism are included in trials evaluating a compound that interferes with this particular mechanism. Extensive pharmacokinetic evaluation of the potential neuropro-tective agent in the injured brain should be required, ensuring adequate tissue penetration once the agent is studied in efficacy trials. A more sensitive analysis of outcome in new types of clinical trials is advocated, with an important role for surrogate outcome measures as well as new types of outcome analysis. Further standardization in treatment is likely to benefit from further development of evidence-based treatment guidelines. Implementation of these suggestions, even though a complex challenge, is likely to improve the chance that experimentally effective agents will show positive results in future clinical trials.
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